The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: clinical cases and a review of the literature by Pagonabarraga, Javier et al.
Journal of Clinical Neuroscience 90 (2021) 178–183Contents lists available at ScienceDirect
Journal of Clinical Neuroscience
journal homepage: www.elsevier .com/ locate/ jocnReview articleThe role of glutamatergic neurotransmission in the motor and
non-motor symptoms in Parkinson’s disease: Clinical cases and a
review of the literaturehttps://doi.org/10.1016/j.jocn.2021.05.056
0967-5868/ 2021 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author at: C/ Mas Casanovas 90, Barcelona 08041, Spain.
E-mail addresses: JPagonabarraga@santpau.cat (J. Pagonabarraga), michele.
tinazzi@univr.it (M. Tinazzi), caccia.carla@gmail.com (C. Caccia), w.jost@parkin-
son-klinik.de (W.H. Jost).Javier Pagonabarraga a,⇑, Michele Tinazzi b, Carla Caccia c, Wolfgang H. Jost d
aMovement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
bNeurology Unit, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy
cCNS Preclinical Pharmacology, Independent Advisor, Milan, Italy
d Parkinson-Klinik Ortenau, Wolfach, Germany
a r t i c l e i n f oArticle history:
Received 18 November 2020





Safinamidea b s t r a c t
Glutamate is the major excitatory neurotransmitter in the central nervous system and, as such, many
brain regions, including the basal ganglia, are rich in glutamatergic neurons. The importance of the basal
ganglia in the control of voluntary movement has long been recognised, with the effect of dysfunction of
the region exemplified by the motor symptoms seen in Parkinson’s disease (PD). However, the basal gan-
glia and the associated glutamatergic system also play a role in the modulation of emotion, nociception
and cognition, dysregulation of which result in some of the non-motor symptoms of PD (depression/anx-
iety, pain and cognitive deficits). Thus, while the treatment of PD has traditionally been approached from
the perspective of dopaminergic replacement, using agents such as levodopa and dopamine receptor ago-
nists, the glutamatergic system offers a novel treatment target for the disease. Safinamide has been
approved in over 20 countries globally for fluctuating PD as add-on therapy to levodopa regimens for
the management of ‘off’ episodes. The drug has both dopaminergic and non-dopaminergic pharmacolog-
ical effects, the latter including inhibition of abnormal glutamate release. The effect of safinamide on the
glutamatergic system might present some advantages over dopamine-based therapies for PD by provid-
ing efficacy for motor (levodopa-induced dyskinesia) as well as non-motor (anxiety, mood disorders,
pain) symptoms. In this article, we discuss the potential role of glutamatergic inhibition on these symp-
toms, using illustrative real-world examples of patients we have treated with safinamide.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Glutamate is the principal excitatory neurotransmitter in the
mammalian central nervous system (CNS). While glutamate is an
important component of a healthy CNS, excessive glutamate con-
centrations or hyperactivity of glutamatergic nerve terminals can
lead to neuronal damage and may be involved in the neurodegen-
eration associated with Parkinson’s disease (PD) [1,2].
Glutamate is synthesised from its precursor glutamine, which is
released from glial cells and taken into presynaptic terminals of
glutamatergic neurons by excitatory amino acid transporters
(EAATs). Here, glutaminase converts glutamine to glutamate. Upon
neuronal stimulation, glutamate is released into the synaptic cleftand binds to pre- and post-synaptic receptors (Fig. 1) [3]. The
effects of glutamate are mediated via activation of two classes of
receptor – ionotropic glutamate receptors (ion channel-linked)
and metabotropic glutamate (mGlu) receptors (G-protein-linked).
Following its binding to receptors, glutamate is removed from
the synaptic cleft by EAATs and glia transporters. The glutamate
taken up into glial cells is converted back to glutamine by glu-
tamine synthetase [4].
The glutamatergic system is involved in various functions of the
healthy brain, including the control of movement via the basal gan-
glia circuitry in direct and indirect pathways (Fig. 2) [4]. In PD, the
degeneration of nigrostriatal dopaminergic neurons causes chain
reactions that ultimately result in glutamatergic overstimulation
of the basal ganglia output nuclei and substantia nigra pars com-
pacta, leading to motor symptoms/motor complications that char-
acterise the disease [5].
Thus, glutamatergic neurotransmission is a potential focus for
pharmacotherapy in PD. This paper describes cases of patients
Fig. 1. Schematic representation of a glutamatergic neuronal synapse, showing the
synthesis and release of glutamate (Glu), its receptors and modes of deactivation.
Glutamine (Gln) is converted to Glu by glutaminase [though glutamate may also be
derived from the TCA cycle (not shown)]. Glu is packaged into presynaptic vesicles
by vesicular Glu transporter (VGluT) proteins and synaptically released in a voltage-
dependent manner through vesicular interactions with SNARE proteins. Synapti-
cally-released Glu is recycled from the extracellular space by excitatory amino acid
transporters (EAATs) expressed predominantly on astroglia. In astrocytes, Glu is
converted to Gln by Gln synthetase and exported extracellularly to be taken up
again by neurons. Additionally, system x-C is a cystine/glutamate antiporter
expressed on glia that also contributes to Glu recycling. Glu receptors are present on
presynaptic and postsynaptic neurons as well as on glial cells. These include both
ionotropic receptors (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
[AMPA], N-methyl-D-aspartate [NMDA] and kainite) and metabotropic receptors
(mGluRs). The effect of Glu is determined by the receptor subtype, localisation
(synaptic, perisynaptic and extrasynaptic) [3]. BDNF, brain derived neurotrophic
factor.
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benzyloxy-benzylamino) propionamide], an agent targeting the
glutamatergic system. Safinamide is a dual-mechanism drug that
acts on both dopaminergic and non-dopaminergic targets, particu-
larly dopaminergic and glutamatergic neurotransmission. It selec-
tively and reversibly inhibits monoamine oxidase-B (MAO-B), thus
restoring striatal dopaminergic tone and reduces subthalamic/ni-
gral glutamatergic hyperactivity through use-dependent sodium
channel blockade, which prevents calcium channel opening and
results in the inhibition of abnormal glutamate release [6,7]. Safi-
namide is approved in over 20 countries globally, including 14 in
the European Union, the United States, and Canada, for the treat-
ment of PD as add-on therapy to levodopa regimens for the man-
agement of ‘off’ episodes (i.e. when levodopa efficacy wanes)
[8,9]. In clinical studies, safinamide significantly reduced ‘off’ time
and increased ‘on’ time without troublesome dyskinesia in patients
receiving levodopa who were experiencing wearing-off phe-
nomenon [10–13].2. Motor symptoms and glutamate
PD is characterised by motor symptoms, including resting tre-
mor, bradykinesia and rigidity in the neck and/or extremities [4].
These symptoms arise primarily as a result of decreased dopamin-
ergic tone due to degeneration of dopamine neurons in the sub-
stantia nigra. This is accompanied by glutamate overactivity in
projections from the subthalamic nucleus, leading to increased
activity in the basal ganglia output nuclei that inhibits the thala-179mus and, ultimately, reduces facilitatory input to motor areas in
the frontal cortex. Consequently, PD patients have difficulty initiat-
ing movement, and once initiated, movement is slow and may be
difficult to stop [4].
Levodopa is a dopamine precursor used to increase dopaminer-
gic neurotransmission in patients with PD. Yet despite treatment,
PD symptoms frequently re-emerge and patients experience fluc-
tuation between mobility and immobility (‘on’ and ‘off’ states,
respectively) [4]. Such motor fluctuations are a significant problem,
since they occur in the majority of patients after a few years of tak-
ing levodopa and significantly impact patients’ mobility and ability
to perform activities of daily living, and they can be difficult to
manage [14]. An additional complication of long-term levodopa
use is troublesome involuntary movements, referred to as
levodopa-induced dyskinesia (LID) [15].
Long-term levodopa treatment is thought to lead to overactivity
of the direct pathway and underactivity of the indirect pathway,
resulting in cortical excitation and dyskinesia [15].While the patho-
physiology of LID is complex, overactivity of glutamatergic corticos-
triatal projections is a critical factor in the dysfunction of the direct
pathway and therefore the development of LID [15]. These findings
suggest that a drug that reduces glutamatergic activity may even
have an anti-dyskinetic effect. Indeed, both safinamide and aman-
tadine (an N-methyl-D-aspartate [NDMA] receptor antagonist)
dose-dependently reduced dyskinesia in a primate model of LID
[16]. Further, abnormal cortical facilitationwas found in PDpatients
experiencing LID (n = 20), indicating overactive glutamatergic neu-
rotransmission in the primary motor cortex [17]. The degree of
abnormality correlated with the severity of dyskinesia. Two weeks’
safinamide treatment normalised cortical facilitation markers.
Importantly, a phase III trial findings suggested safinamide may
have a positive impact in patients with moderate-to-severe dyski-
nesia at baseline [11]. The case reported below provides real-
world evidence of successful management of motor fluctuations
and a reduction in LID after safinamide initiation.
2.1. Case report 1
A 65-year-old male diagnosed with PD 6 years previously (con-
firmed by Betacid-SPECT, with normal findings on magnetic reso-
nance imaging) had initial symptoms of resting tremor of the
legs and right arm, and hyposmia. Levodopa/carbidopa/entacapone
100/25/200 mg/day was initially prescribed. Two years later, trans-
dermal rotigotine patch (4 mg/24 h) was prescribed, but this was
associated with the onset of psychosis. Clozapine 12.5 mg/day
was then added, resulting in a reduction in hallucinations and good
control of tremor (clozapine is used in our hospital as treatment of
last resort for therapy-resistant tremor with good effect [18]). One
year later, the patient had developed wearing off and end-of-dose
dyskinesias while receiving levodopa 400 mg/day. Safinamide was
initiated at 50 mg/day and 2 weeks later increased to 100 mg/day.
This was associated with good effects on motor fluctuations and
dyskinesia, as shown by a decrease in the patient’s total Unified
Parkinson’s Disease Rating Scale (UPDRS) score in the on state from
65 before safinamide to 59 during safinamide. The most marked
improvement was seen in UPDRS Part IV, which changed from 9
to 5; other UPDRS subscores showed small decreases (Part II from
19 to 18 and Part III from 36 to 35) or remained unchanged (Part I
was 1 before and during safinamide). However, the patient stopped
taking safinamide 6 months later because of leg oedema (the
patient suspected a relationship and could not be convinced other-
wise; he would not consider rotigotine as a possible cause because
he did not want to discontinue it). The leg oedema did not resolve
after discontinuing safinamide. Rasagiline 1 mg/day was pre-
scribed in place of safinamide, with no reduction of his leg oedema,
and the dyskinesia and motor fluctuations re-emerged. At consul-
Fig. 2. The role of neurotransmitters in the basal ganglia functional motor circuitry. D1/D2 = dopamine type 1 or 2 receptors expressed in striatal neurons; GABA = gamma-
aminobutyric acid; GPe = external globus pallidus; GPi = internal globus pallidus; SNc = substantia nigra pars compacta; SNr = substantia nigra pars reticulata; VA/VL = ventral
anterior/ventral lateral [4].
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amantadine because of the previous hallucinations and a QTc of
452 ms. Rasagiline was stopped and safinamide was restarted
(50 mg/day for 2 weeks, then 100 mg/day). The higher dosage
was also associated with good reductions in dyskinesia and motor
fluctuations; his UPDRS score was then 59. The leg oedema
remained unchanged.
The above case illustrates the importance of effective motor
control for patients with PD. In this patient, safinamide signifi-
cantly improved motor symptoms, including LID. Although the
patient believed safinamide had caused his leg oedema, leading
him to discontinue its use, the most likely causative agent was
the dopamine agonist rotigotine. Further, the superior effect of
safinamide in controlling motor fluctuations compared with rasag-
iline meant it was reintroduced and became the therapy of choice
for this patient.3. Non-motor symptoms and glutamate
The occurrence of non-motor symptoms, including pain,
depression and anxiety, is a significant component of PD. Indeed,
patients often refer to non-motor disturbances as being even more
distressing and disabling than the classical motor symptoms of PD.
Non-motor symptoms can be problematic at all stages of disease
development, including early PD, where symptoms such as consti-
pation and loss of smell can have a detrimental impact on daily life
[19]. In advanced PD, non-motor complications, such as hallucina-
tions, cognitive impairment, depression and autonomic distur-
bances, have been described as the predominant problems,
occurring in 70% of patients [20,21]. Maintenance of QOL is a sig-
nificant unmet need in PD management, and effective treatment of
non-motor symptoms should lead to improved QOL.1803.1. Pain in Parkinson’s disease
Pain is prevalent in patients with PD, estimated to affect 68–
95% of patients, depending on the type of pain assessed [22]. Pain
in PD is classified into five different types: musculoskeletal (felt as
an ache around the joints, arms or legs), dystonia-related, radicular
or neuropathic, primary/central and akathisia-related [22]. There is
a high incidence of depression and reduced QOL in patients with
PD who report pain symptoms [23]. Pain in patients with PD is
poorly managed and characterised by underuse of analgesics [23].
There is clinical evidence that pain may be a premotor sign in
early disease [24]. PD patients may also be predisposed to the
development of pain, as evidenced by a low heat pain threshold
and abnormal pain-evoked responses in PD patients both with
and without pain (whether in an ‘on’ or ‘off’ state) [25,26]. This
suggests that the increased risk of pain may be linked to PD patho-
physiology. The nigrostriatal damage associated with PD may dis-
rupt the usual control by the basal ganglia of cerebral areas that
process nociceptive input [27]. Abnormal central nociceptive pro-
cessing may result from nigral and extra-nigral pathology, involv-
ing the cortical areas, brainstem nuclei and spinal cord [28].
While the neurobiology of pain in PD is complex, involving mul-
tiple neurotransmitter systems [29] the glutamatergic system is of
particular interest because of its role in pathophysiological noci-
ception [2]. The primary afferent neurons that transmit peripheral
sensory information and pain signals to the spinal cord are mostly
glutamatergic; stimulation results in the excessive release of gluta-
mate from central terminals in the spinal cord and the activation of
ionotropic receptors on secondary neurons [2]. Abnormal central
nociceptive processing can be targeted using antagonists of iono-
tropic glutamate receptors, including NMDA, a-amino-3-hydrox
y-5-methyl-4-isoxazolepropionic acid and kainate receptor antag-
onists, which decrease nociceptive transmission [30]. However,
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adverse effects. The development of selective mGluR ligands has
allowed researchers to further investigate the role of glutamate
in the modulation and control of pain [31] and whether they can
potentiate the effect of other drugs (such as antidepressants or opi-
oids) used in neuropathic pain therapy.
Post-hoc analyses of 24-week and 2-year studies of safinamide
examined the effect of the drug on concomitant pain treatments
and scores on pain-related items of the Parkinson’s Disease Ques-
tionnaire  39 (PDQ39) [32,33]. The analyses found significant
improvements in ‘painful cramps or spasms’ and ‘unpleasantly
hot or cold’ scores, and a significant reduction in the number of
concomitant pain treatments, with significantly more patients
receiving safinamide than placebo not using pain treatments at
the end of the treatment periods.
The PAINinPD study [34] directly assessed the effect of safi-
namide on pain in 13 patients with mild-to-moderate PD, motor
fluctuations while receiving levodopa and a history of pain for
the preceding 12 weeks who received safinamide 100 mg/day for
12 weeks. Pain was assessed using the King’s Parkinson’s Disease
Pain Scale (KPPS), the Intensity and Interference subscales of the
Brief Pain Inventory (BPI), and the Numerical Rating Scale (NRS)
[primary outcomes]. Secondary outcomes included effects on the
PDQ39, Clinical Global Impression of Change (CGI-C) and UPDRS
parts III and IV. Significant effects were seen on all primary out-
comes, and on the UPDRS parts III and IV, PDQ39 total and bodily
discomfort scores, CGI-C and proportion of pain responders (de-
fined as those patients having a >50% improvement from baseline
on the NRS). No correlation was found between the mean change
in UPDRS part III-IV and any pain outcome, except for a correlation
between change in the UPDRS part IV and the NRS score. These
results, along with others from previous post-hoc analyses and
meta-analyses [32,33,35], indicate that safinamide mainly directly
affects pain in PD and only partially improves pain through an indi-
rect pathway secondary to the improvement in motor complica-
tions, probably through its dual mechanism of action. The next
case report discusses the use of safinamide in a patient from the
PAINinPD study.
3.2. Case report 2
A 68-year-old male first presented 10 years previously with tre-
mor and bradykinesia/rigidity of the right (dominant) hand. Initial
treatment was pramipexole prolonged-release (PR) 1.05 mg/day
and selegiline 5 mg/day, which provided significant improvement
of both tremor and bradykinesia. Over the next 5 years, the clinical
picture remained stable with resting tremor localised to the upper
right limb and bradykinesia/rigidity to both right upper and lower
limbs. At 5 years after treatment initiation, the dosage of
pramipexole PR was 1.57 mg/day and of selegiline was 10 mg/day.
His bradykinesia/rigidity of the right limbs had worsened and
spread to both the left upper and lower limbs. For this reason,
levodopa/carbidopa 100/25 mg three times/day was added, which
resulted in significant improvements in parkinsonian motor
symptoms.
Over the following years, the patient developed motor compli-
cations characterised by wearing-off phenomena and nocturnal
bradykinesia associated with musculoskeletal, radicular neuro-
pathic and dystonic pain localised to the lumbar back and lower
limbs, which was only partially improved by increasing levodopa/-
carbidopa 100/25 mg to five times/day.
This patient was then enrolled in the PAINinPD study. The
patient was examined in the ‘on’ phase before and 12 weeks after
add-on therapy with safinamide 100 mg/day. A significant
improvement between baseline and the final assessment was
observed for the following scores: total KPPS (48 vs 24), BPI Inten-181sity (20 vs 14), BPI Interference (53 vs 15), NRS (9 vs 2), PDQ39
bodily discomfort (8 vs 4), UPDRS part III (21 vs 8), UPDRS part
IV (9 vs 4), and total PDQ39 (48.72 vs 30.77). No treatment-
emergent adverse effects were reported in this patient.
The improvement of motor fluctuations seen in the above
patient after safinamide initiation (i.e. reduction of UPDRS part III
and IV scores) was as expected. However, independent of the
motor improvement, this case confirms the effect of safinamide
on pain symptoms. The fact that pain was present and persisted
despite the use of dopaminergic agents (pramipexole and levo-
dopa) suggests that the unique anti-glutamatergic properties of
safinamide may have been responsible for its effects on this non-
motor symptom. Indeed, a recent systematic review and meta-
analysis found that safinamide was the most efficacious among
all studied therapies for reducing pain in PD [35].
3.3. Anxiety and mood disorders
Depression and anxiety are common in PD, occurring with a
prevalence of approximately 17% and 31%, respectively [36,37],
although frequencies vary between studies. Mood disorders have
a significant negative impact on a patient’s prognosis and QOL [38].
Depression and anxiety are thought to develop before dopa-
mine cell loss in the substantia nigra pars compacta, and therefore
before motor symptoms are evident. They may originate from
brainstem monoamine pathology affecting the locus coeruleus
and dorsal raphe nucleus at the early stages of the disease
[39,40], whereas depression and anxiety manifesting later in the
course of PD probably reflect alterations in multiple neurotrans-
mitter pathways [40]. These changes primarily affect the
monoamines (such as dopamine, noradrenaline, and serotonin)
[39] but there is increasing evidence from preclinical and clinical
studies for the involvement of glutamatergic and GABAergic trans-
mission in depression and anxiety in PD [2].
Proof-of-concept regarding the involvement of the glutamater-
gic system in mood disorders was based on clinical data with keta-
mine, an NMDA receptor antagonist found to exert a rapid
antidepressant effect in patients with depression [41]. Post-
mortem studies provide evidence of glutamate abnormalities in
mood disorders [42] and magnetic resonance spectroscopy studies
found increased glutamate and/or glutamine levels in the basal
ganglia of patients with depression [43,44]. In preclinical models
of depression, striatal mGlu5 receptor expression was increased,
leading to hyperactivity of mGlu5 receptor signalling [45] and
thereby contributing to depression-like symptoms, which are pre-
vented by mGluR5 antagonists [46–48].
Anxiety disorders are also associatedwith glutamate hyperactiv-
ity, especially in excitatory synapses of the amygdala, which like the
basal ganglia, form part of the limbic system. Limbic and paralimbic
brain structures have been extensively implicated in the mediation
of fear and anxiety, and are richly innervated by glutamatergic pyra-
midal cells [49,50]. Drugs such as NMDA and AMPA receptor antag-
onists and allosteric mGluR modulators have anxiolytic effects
according to studies in animal models and in humans [51].
Clinical studies have shown an effect of safinamide on mood
symptoms in patients with PD. For example, Cattaneo et al. [52]
performed a post-hoc analysis of two phase III trials of safinamide
that focused on mood outcomes. They found significant improve-
ments in mood as determined by the ‘emotional well-being’
domain of the 39-item Parkinson’s disease questionnaire
(PDQ39). In addition, real-world clinical practice data in patients
with PD and depression showed an improvement in depression
symptoms (based on the Hamilton Depression Rating Scale) 1
and 3 months after starting safinamide [53]. In a recent open-
label prospective study specifically designed to assess the change
in non-motor symptom burden in PD patients after initiating treat-
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mood status was found using the Non-Motor Symptoms Scale,
Beck Depression Inventory-II and the emotional wellbeing domain
of PDQ-39 [54].
The following real-world case specifically illustrates the effect
of safinamide on anxiety.
3.4. Case report 3
A 58-year-old woman was diagnosed with PD after presenting
with resting tremor and re-emergent postural tremor in her left
hand, bilateral asymmetric rigid-akinetic syndrome predominant
on her left side and persistent pain in her left shoulder. Her gait
was slow with decreased left arm swing. In addition to motor
symptoms, she reported increasing anxiety and mood instability
during the previous 2 years, reporting worrying about her temper
and medical condition, losing interest in her usual activities and
troubles with concentrating. Passage hallucinations were reported
when she was directly asked about different perceptual problems.
Rotigotine 4 mg/day was initiated, which improved the
patient’s anxiety, motivation and shoulder pain; there were clear
improvements in her slowness, rigidity and tremor only after the
dosage was increased to 8 mg/day.
Three years after starting treatment with rotigotine, and in
order to better control her resting tremor, levodopa 150 mg three
times daily (450 mg/day) was added, with good control of tremors
and improvement of general mobility and hand dexterity. Two
years later, the patient reported worsening anxiety, lack of energy
and motivation. The pain in her shoulder had returned, and symp-
toms in her left foot had characteristics of early morning akinesia
or an initial manifestation of wearing-off. She reported that her
anxiety was the symptom that fluctuated most during the day,
and that 15–20 min after taking levodopa, the symptoms improved
or dissipated. Despite frequent fatigue and anergia, she had diffi-
culty falling asleep because of inner tension and uncomfortable
generalised body sensations. The Neuropsychiatric Fluctuations
Scale for PD detected severe inability to relax during ‘off’ episodes,
with associated mild sadness, lack of energy and confidence, and
concentration difficulties. No specific neuropsychiatric symptoms
were detected during ‘on’ periods. By using a visual analogue scale
(VAS = 0–10) the patient’s ‘off’ episodes were characterised pre-
dominantly by anxiety (9/10), fatigue (8/10), pain (6/10) and mild
sadness (2/10). During the follow-up after starting safinamide
therapy, changes in anxiety, fatigue, anergia, and pain were subse-
quently assessed by VAS for each symptom.
Safinamide 50 mg/day was initiated. During the first month of
treatment, ‘off’ episode duration decreased from 45 to 60 min to
15 min before the 14:00 h levodopa dose, with no new episodes
of fatigue and anergia in the evenings; episodes of early-morning
anxiety were still present (VAS 4/10). At 1 month, safinamide
was increased to 100 mg/day (taken in the morning), and 2 weeks
later, her anxiety had completely resolved, both when she was
walking at midday and when waking up (VAS 0/10), and no epi-
sodes of foot dystonia appeared. Six months after starting safi-
namide, the patient remained free of wearing-off phenomena,
and the improvements in her anxiety, fatigue, anergia and shoulder
pain had had a major impact on her daily life and family
relationships.
The above case illustrates the complexity of symptoms seen in
patients with PD and the differing impact of each PD symptom for
patients. Over her disease course, this patient had presented with
both classic motor symptoms and some non-motor symptoms
(pain and anxiety). It appears that the latter symptoms, particu-
larly anxiety, most significantly affected her QOL. While the effect
of safinamide on anxiety may simply reflect a dopaminergic effect,
prior dopamine-based therapy (rotigotine and levodopa) were not182able to manage the full constellation of symptoms experienced by
the patient. It was only when a non-dopaminergic agent (i.e. the
anti-glutamatergic effect of safinamide) was added that all the
patient’s symptoms were well controlled.
4. Conclusions
Glutamatergic neurotransmission within the basal ganglia is
involved in the development of numerous symptoms in patients
with PD, from classic motor symptoms to non-motor symptoms,
such as anxiety/mood disorders and pain. This neurotransmission
is, therefore, an additional target for the pharmacotherapy of PD.
Safinamide is an approved treatment for PD with a unique
mechanism of action that includes inhibition of excessive gluta-
mate release when nerve terminals are overactive. While the direct
effects of safinamide on glutamate release have only been demon-
strated in animal models [6,7,55,56], there is indirect evidence of
such an effect in humans [17]. Safinamide as add-on therapy to
levodopa reduces ‘off’ time and increases ‘on’ time without trou-
blesome dyskinesia [10–13], and may be effective in managing
pain and mood disorders. Other PD drugs, including other MAO-B
inhibitors, do not share safinamide’s anti-glutamatergic effects,
which may explain its effectiveness for both motor and non-
motor symptoms. It must be noted, however, that the clinically rel-
evant improvements in motor symptoms occurring during safi-
namide can contribute considerably to the improvement of non-
motor symptoms.
Clinical trial data provides robust evidence on efficacy and tol-
erability in highly selected groups of patients, whereas data from
real-world studies and case reports (such as those described here)
can provide useful additional information, such as effects on symp-
toms that may not have been assessed directly in clinical trials. The
cases described in this article illustrate clinical scenarios where
safinamide is an appropriate choice as add-on treatment in
patients with PD.
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